 |
|
Elimination of hepatitis C: What would be the practical approach?
Hyung Joon Yim
Clin Mol Hepatol. 2021;27(1):97-99. Published online 2020 Dec 3 DOI: https://doi.org/10.3350/cmh.2020.0304
|
|
Citations to this article as recorded by
 Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo
The Korean Journal of Internal Medicine.2022; 37(6): 1167. CrossRef The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients
Yu Jun Wong, Prem Harichander Thurairajah, Rahul Kumar, Kwong Ming Fock, Ngai Moh Law, Sin-Yoong Chong, Fria Gloriba Manejero, Tiing-Leong Ang, Eng Kiong Teo, Jessica Tan
Clinical and Molecular Hepatology.2021; 27(3): 474. CrossRef
|